Key result
Intravenous delivery of TAT.p27 fusion protein post-myocardial infarction in rats decreased cardiac apoptosis, reduced hypertrophy and fibrosis, and improved cardiac function and survival at 28 days.
Why the study?
Does intravenous delivery of TAT-p27 fusion protein improve cardiac function and survival in rodent models of myocardial infarction?
Does intravenous delivery of TAT-p27 fusion protein improve cardiac function and survival in rodent models of myocardial infarction?
Intravenous delivery of a TAT-p27 fusion protein reduces adverse cardiac remodeling, improves heart function, and increases survival in rodent models of myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Should not yet inform clinical practice; leaves open TAT-p27 as a candidate therapy for post-MI remodeling pending larger studies.
Konečný et al. (2012) studied Myocardial infarction. TAT-p27 fusion protein (TAT.p27) vs. Saline and TAT.LacZ was evaluated on Cardiac apoptosis, hypertrophy, fibrosis, cardiac function, and survival. Intravenous delivery of TAT.p27 fusion protein post-myocardial infarction in rats decreased cardiac apoptosis, reduced hypertrophy and fibrosis, and improved cardiac function and survival at 28 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: